Hemoglobin Desaturation in Sickle Cell Disease
19. mai 2022 oppdatert av: Lalitha Nayak, University Hospitals Cleveland Medical Center
Hemoglobin Desaturation and RBC Adhesion: Potential Therapeutic Targets in Sickle Cell Disease
As part of routine care for SCD, some people are found to have low oxygen levels (≤ 88%) while sleeping, at rest, or with exercise.
Testing is done with a small portable device positioned on the finger that measures oxygen levels during sleep, at rest, or following exercise.
The investigators start oxygen treatment for people with low levels of oxygen.
As a part of this study, the investigators will find out if any changes in cell "stickiness" occur with low oxygen levels (at rest, at night, or with exertion) and if cells become "less sticky" with oxygen treatment.
Study subjects will be seen before testing and 2 months after testing.
In some cases (people with low oxygen levels during testing), study subjects will have been prescribed oxygen, and the investigators will test the effects of that treatment on the stickiness of red cells.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
In SCD, exertional hypoxia and nocturnal hemoglobin desaturation (NHD, or hemoglobin deoxygenation during sleep) are common, treatable, and associated with bad outcomes in children and young adults15,16. The median life-expectancy of SCD has risen dramatically in the last 40 years. One consequence of this is an expanding young adult population in whom the comorbidities are not yet fully characterized. The prevalence, clinical consequences, and treatment outcomes of exertional hypoxia and NHD are poorly described in adults with SCD. Therefore, it is important to identify and better understand any clinically significant hypoxia (during exercise or sleep or at rest) in this expanding adult population. The investigators will study whether RBC adhesion at baseline and when exposed to hypoxia in vitro is significantly increased in adult HbSS patients with baseline hypoxia, exertional hypoxia or nocturnal NHD due to RBC membrane changes arising from prolonged in vivo exposure to hypoxia, which may be mitigated by oxygen therapy.
Hypotheses: The investigators hypothesize that disease activity and RBC adhesion (under normoxia) will be greater in subjects with HbSS plus baseline in vivo hypoxia, exertional hypoxia, or NHD, due to RBC membrane damage from prolonged hypoxia in vivo. Successful treatment with therapeutic oxygen, at baseline, with exertion, or during sleep, may decrease RBC adhesion in vitro.
Specific Aim 1: To evaluate for resting hypoxia, exertional hypoxia or NHD, and its clinical associations, in adults with HbSS.
Specific Aim 2: To examine baseline RBC adhesion under normoxia or hypoxia in vitro in adults with HbSS, with and without in vivo resting or exertional hypoxia or NHD.
Specific Aim 3: To examine serial changes in S-RBC adhesion at baseline and with hypoxia in vitro, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen.
The investigators are testing whether:
- Subjects with Hb desaturation at baseline, with exertion, or during sleep (NHD), compared to those without, will have increased disease activity (exertional or nocturnal symptoms, priapism, WBC activation, reticulocytosis, and/or hemolysis).
- S-RBCs from subjects with clinical Hb desaturation at rest, with exertion, or during sleep, compared to those without, will have increased adhesion at baseline and when exposed to hypoxia in vitro.
2.A. Treatment of baseline hypoxia, exertional hypoxia, and/or NHD with supplemental oxygen will decrease S-RBC adhesion and HEA, and may decrease symptoms, especially night- time symptoms.
Studietype
Observasjonsmessig
Registrering (Faktiske)
1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- University Hospitals Cleveland Medical Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Individuals with HbSS Sickle Cell Disease
Beskrivelse
Inclusion Criteria:
- Male or Female > 18 year of age at the time of consent.
- Documentation of Sickle Cell Disease, phenotypically HbSS (including S-Beta 0 thalassemia)
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
- English speaking patient
Exclusion Criteria:
- Ongoing Oxygen therapy.
- active pregnancy, due to complex pathophysiology during that interval.
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. -
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluation for resting hypoxia
Tidsramme: Through study completion, up to approximately 4 years
|
We will test resting SpO2 and night-time oxymetry to obtain Hb saturation results.
|
Through study completion, up to approximately 4 years
|
|
Evaluation for exertional hypoxia
Tidsramme: Through study completion, up to approximately 4 years
|
We will evaluate 6MWT results and obtain Hb saturation results.
|
Through study completion, up to approximately 4 years
|
|
Evaluation of hypoxia and its effect on CBC
Tidsramme: Through study completion, up to approximately 4 years
|
CBC results will be evaluated
|
Through study completion, up to approximately 4 years
|
|
Evaluation of hypoxia and its effect on reticulocyte count
Tidsramme: Through study completion, up to approximately 4 years
|
Reticulocyte count will be evaluated
|
Through study completion, up to approximately 4 years
|
|
Evaluation of hypoxia and its effect on LDH
Tidsramme: Through study completion, up to approximately 4 years
|
LDH level will be evaluated
|
Through study completion, up to approximately 4 years
|
|
Evaluation of hypoxia and its effect on serum chemistry
Tidsramme: Through study completion, up to approximately 4 years
|
Serum chemistry through a comprehensive panel will be evaluated
|
Through study completion, up to approximately 4 years
|
|
Evaluation of patient's incidence of hypoxia-related symptoms
Tidsramme: Through study completion, up to approximately 4 years
|
Incidence of hypoxia-related symptoms will be obtained from review of the patient's chart and approved symptom questionnaire.
|
Through study completion, up to approximately 4 years
|
|
Evaluation of hypoxia and its effect on echocardiogram results
Tidsramme: Through study completion, up to approximately 4 years
|
Screening echocardiogram
|
Through study completion, up to approximately 4 years
|
|
Evaluation of patient's incidence of hypoxia-related nocturnal symptoms
Tidsramme: Through study completion, up to approximately 4 years
|
Incidence of nocturnal hypoxia-related symptoms will be obtained from review of the patient's chart and approved symptom questionnaire.
|
Through study completion, up to approximately 4 years
|
|
Examination of amount of baseline RBC adhesion and HEA in vitro in adults with HbSS
Tidsramme: Through study completion, up to approximately 4 years
|
Amount of S-RBC adhesion to LN on the SCD and Hypoxia Biochips will be quantitated, using <400 μL surplus whole blood in EDTA, obtained during routine clinical care (as published previously1,6-8), at the clinic visit immediately prior to night-time oximetry and 6MWT
|
Through study completion, up to approximately 4 years
|
|
Examination of baseline FACS results in adults with HbSS
Tidsramme: Through study completion, up to approximately 4 years
|
Fluorescent Activated Cell Sorting (FACS) following incubation with antibodies to CD14, CD16, and CX3CR1 will be performed on 3-400 μL of surplus whole blood.
|
Through study completion, up to approximately 4 years
|
|
Examination of amount of baseline RBC adhesion and HEA in vitro in adults with HbSS
Tidsramme: Through study completion, up to approximately 4 years
|
Simple t-tests will be used to compare RBC adhesion, HEA to LN and monocyte activation in patients with clinically significant hypoxia and those without any hypoxia
|
Through study completion, up to approximately 4 years
|
|
Examination of serial changes in incidence of nocturnal symptoms at baseline and with hypoxia, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen.
Tidsramme: 2 months
|
At ~2 months after initial testing (and >6 weeks on treatment, if needed), all subjects will be re-evaluated for incidence of hypoxia-related nocturnal symptoms through review of the patient's chart and approved symptom questionnaire
|
2 months
|
|
Examination of serial changes in amount of S-RBC adhesion at baseline and with hypoxia in vitro, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen
Tidsramme: 2 months
|
At ~2 months after initial testing (and >6 weeks on treatment, if needed), all subjects will be re-evaluated for amount of RBC adhesion
|
2 months
|
|
Examination of serial changes in incidence of hypoxia-related symptoms at baseline and with hypoxia, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen.
Tidsramme: 2 months
|
At ~2 months after initial testing (and >6 weeks on treatment, if needed), all subjects will have incidence of hypoxia-related symptoms re-evaluated through review of the patient's chart and approved symptom questionnaire
|
2 months
|
|
Examination of serial changes in Hb saturation at baseline and with hypoxia in vitro, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen
Tidsramme: 2 months
|
We will repeat Hb saturation testing
|
2 months
|
|
Examination of serial changes in amount of S-RBC adhesion at baseline and with hypoxia in vitro, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen.
Tidsramme: 2 months
|
Paired t-test on S-RBC adhesion to LN and HEA before and after oxygen therapy, in subjects with and without clinically significant hypoxia will be performed
|
2 months
|
|
Examination of serial changes in amount of WBC activation at baseline and with hypoxia in vitro, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen
Tidsramme: 2 months
|
Amount of WBC activation will be determined
|
2 months
|
|
Examination of serial changes in CBC at baseline and with hypoxia in vitro, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen.
Tidsramme: 2 months
|
CBC results will be examined for any suggestive changes
|
2 months
|
|
Examination of serial changes in reticulocyte count at baseline and with hypoxia in vitro, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen.
Tidsramme: 2 months
|
Reticulocyte count will be examined for any suggestive changes
|
2 months
|
|
Examination of serial changes in LDH at baseline and with hypoxia in vitro, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen.
Tidsramme: 2 months
|
LDH level will be examined for any suggestive changes
|
2 months
|
|
Examination of serial changes in serum chemistry at baseline and with hypoxia in vitro, in adults with HbSS and resting or exertional hypoxia or NHD, before and after therapeutic intervention with oxygen.
Tidsramme: 2 months
|
Serum chemistry through a comprehensive panel will be examined for any suggestive changes
|
2 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Jane Little, MD, University Hospitals Cleveland Medical Center
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
23. mars 2018
Primær fullføring (Faktiske)
1. februar 2022
Studiet fullført (Faktiske)
1. februar 2022
Datoer for studieregistrering
Først innsendt
21. mars 2019
Først innsendt som oppfylte QC-kriteriene
5. april 2019
Først lagt ut (Faktiske)
9. april 2019
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
26. mai 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
19. mai 2022
Sist bekreftet
1. mai 2022
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 03-18-23
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sigdcellesykdom
-
Second Affiliated Hospital of Guangzhou Medical...Hunan Zhaotai Yongren Medical Innovation Co. Ltd.RekrutteringAnti-kreft celle immunterapi | T Cell og NK CellKina
-
Peking University People's HospitalUkjentNatural Killer Cell Medited ImmunitetKina
-
Center for International Blood and Marrow Transplant...Cellular Dynamics International, Inc. - A FUJIFILM CompanyAvsluttetiPS Cell Manufacturing and Banking
-
Medtronic - MITGAvsluttetEsophageal squamous cell neoplasia (ESCN)Kina
-
Assistance Publique - Hôpitaux de ParisHar ikke rekruttert ennå
-
Bing HanFullførtPure Red Cell Aplasia, ervervetKina
-
Debiopharm International SARekrutteringPankreas duktal adenokarsinom (PDAC) | Kolorektal kreft (CRC) | Clear Cell Renal Cell Cancer (ccRCC)Frankrike, Australia
-
Calla IVF CenterFullførtImmunmodulerende legemidler | Killer-cell immunoglobulin-lignende reseptorer (KIR) | KIR Alleles (KIR AA)Romania
-
Institute of Hematology & Blood Diseases Hospital...AvsluttetErvervet Pure Red Cell AplasiaKina
-
National Cancer Institute (NCI)RekrutteringTilbakevendende Langerhans Cell Histiocytose | Refraktær Langerhans Cell HistiocytoseForente stater, Canada